Showing results (31-40 of 50) with videos related to
Sort By:
Pageof 5
Neurology|February 9, 2021
Funding the Educational Mission in NeurologyDavid M Greer, Jeremy Moeller, Diego R Torres, et al.Advances in Therapy|May 20, 2021
Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label StudyJai Perumal, Roumen Balabanov, Ray Su, et al.Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association|July 22, 2020
Hemorrhagic stroke and anticoagulation in COVID-19Siddhant Dogra, Rajan Jain, Meng Cao, et al.Neurology(R) Neuroimmunology & Neuroinflammation|December 14, 2022
MOG Antibody-Associated Disease and Thymic Hyperplasia: From the National Multiple Sclerosis Society Case Conference ProceedingsBrigitte Hurtubise, Elliot M Frohman, Steven Galetta, et al.Neurology(R) Neuroimmunology & Neuroinflammation|November 10, 2022
Recurrent Optic Neuritis and Perineuritis Followed by an Unexpected Discovery: From the National Multiple Sclerosis Society Case Conference ProceedingsDaniela A Pimentel Maldonado, Robert Lisak, Steven Galetta, et al.Neurology|May 3, 2014
Retinal architecture and mfERG: Optic nerve head component response characteristics in MSZane S Schnurman, Teresa C Frohman, Shin C Beh, et al.The Lancet. Neurology|February 10, 2009
Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) studyEva Havrdova, Steven Galetta, Michael Hutchinson, et al.Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 13, 2022
Comparison of serum neurodegenerative biomarkers among hospitalized COVID-19 patients versus non-COVID subjects with normal cognition, mild cognitive impairment, or Alzheimer's dementiaJennifer A Frontera, Allal Boutajangout, Arjun V Masurkar, et al.The Lancet. Neurology|February 24, 2017
Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trialDiego Cadavid, Laura Balcer, Steven Galetta, et al.Annals of Clinical and Translational Neurology|October 24, 2018
Predictors of response to opicinumab in acute optic neuritisDiego Cadavid, Laura Balcer, Steven Galetta, et al.Pageof 5